Tenon Medical, Inc.
No SEC Form 4 filings for $TNON in the last 30 days.
See all $TNON insider activity →Tenon Medical, Inc. (TNON) said it will conduct a 1-for-35 reverse stock split effective Aug. 10, 2026 at 12:01 ET. Shares will trade on a split-adjusted basis under the same ticker, with a new CUSIP. The move follows shareholder approval on July 23 and aims to meet Nasdaq’s $1.00 average closing price requirement. No fractional shares will be issued.
Tenon Medical, Inc. (NASDAQ:TNON) announced a 1-for-35 reverse stock split of its common stock, effective August 10, 2026 before Nasdaq trading. Stockholders approved the split at the July 23, 2026 annual meeting to help meet Nasdaq’s $1.00 minimum average closing price requirement. Vstock Transfer will act as exchange agent; no fractional shares will be issued.
Tenon Medical, Inc. (TNON) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001560293 0001560293 2026-07-23 2026-07-23 0001560293 TNON:CommonStockParValue0.001PerShareMember 2026-07-23 2026-07-23 0001560293 TNON:WarrantsMember 2026-07-23 2026-07-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION W
Over the past 7 days, alphai's AI scored 2 news stories mentioning TNON (Tenon Medical, Inc.). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent TNON coverage spans corporate actions, financial news and regulation.
The reverse split is a mechanical price adjustment to maintain Nasdaq listing compliance, with limited fundamental change but potential near-term liquidity and volatility effects.
The split is a listing-compliance action that can mechanically reset per-share metrics and may signal financial stress, increasing near-term trading volatility.
Shareholder approval clears key Nasdaq compliance and financing mechanics, including a reverse split and issuance limits tied to prior debt financing.
The filing signals a capital-raise/financing transaction via a securities purchase agreement and warrants, which can affect dilution and near-term funding expectations.
Regulatory clearance for upgraded, reusable instrumentation should support adoption and improve unit economics via lower per-procedure costs.
alphai scores every news story that mentions TNON with an AI model for sentiment and relevance, and aggregates insider trades from Tenon Medical, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Tenon Medical, Inc. (TNON) said it will conduct a 1-for-35 reverse stock split effective Aug. 10, 2026 at 12:01 ET. Shares will trade on a split-adjusted basis under the same ticker, with a new CUSIP. The move follows shareholder approval on July 23 and aims to meet Nasdaq’s $1.00 average closing price requirement. No fractional shares will be issued.
3 min readTenon Medical, Inc. (NASDAQ:TNON) announced a 1-for-35 reverse stock split of its common stock, effective August 10, 2026 before Nasdaq trading. Stockholders approved the split at the July 23, 2026 annual meeting to help meet Nasdaq’s $1.00 minimum average closing price requirement. Vstock Transfer will act as exchange agent; no fractional shares will be issued.
2 min readTenon Medical, Inc. (TNON) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001560293 0001560293 2026-07-23 2026-07-23 0001560293 TNON:CommonStockParValue0.001PerShareMember 2026-07-23 2026-07-23 0001560293 TNON:WarrantsMember 2026-07-23 2026-07-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION W
3 min readTenon Medical, Inc. (TNON) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 6 ea029678001ex10-1.htm FORM OF SECURITIES PURCHASE AGREEMENT Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “ Agreement ”) is entered into and made effective as of June 29, 2026, by and between TENON MEDICAL, INC., a Delaware corporat
4 min readTenon Medical (NASDAQ:TNON) said the FDA granted 510(k) clearance for an updated Catamaran SI Joint Fusion System. The update includes instrument upgrades and reclassifying some instruments from disposable to reusable to remove per-procedure disposable costs. Tenon cited 1,500+ Catamaran fixation devices implanted since its Oct 2022 launch.
3 min readWallachBeth Capital LLC said Tenon Medical, Inc. (NASDAQ: TNON) closed a $4.2 million public offering. It sold 11,052,631 shares (or pre-funded warrants) at $0.38 per share plus warrants for up to 13,263,159 shares. Net proceeds will partly repay convertible notes and fund sales, R&D, inventory, and other uses.
3 min readTenon Medical (NASDAQ:TNON) said it closed a public offering raising about $4.2 million in gross proceeds at a $0.38 per-share price. The deal included 11.05M shares (or pre-funded warrants) and warrants for up to 13.26M shares (16.58M after a potential reverse split). Net proceeds will repay convertible notes and fund sales, R&D, clinical studies, inventory, and general purposes.
4 min readTenon Medical, Inc. (TNON) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001560293 0001560293 2026-02-26 2026-02-26 0001560293 TNON:CommonStockParValue0.001PerShareMember 2026-02-26 2026-02-26 0001560293 TNON:WarrantsMember 2026-02-26 2026-02-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION W
2 min readTenon Medical (TNON) recently completed a private placement, raising $4.3 million through senior convertible promissory notes. These notes, maturing in September 2026, are convertible into common stock at a discount to recent trading prices. The company plans to use the proceeds for commercial expansion, product development, clinical studies, and general corporate purposes, aiming to strengthen its growth in the SI joint device market.
2 min readTenon Medical, Inc. has successfully closed a private placement of senior convertible promissory notes, raising an aggregate gross proceeds of $4.3 million. The funds are earmarked for commercial expansion, product development, clinical studies, working capital, and general corporate purposes. The notes are convertible into shares of the Company's common stock at a conversion price equal to 80% of the VWAP for the three trading days immediately prior to the conversion date.
2 min read
